Concurrent Session 4B: Advancing Care Through Epigenomics; CME (AMA PRA Category 1 CreditsTM) 1.5; Attendance CEU 1.5

Thursday, September 13
1:45 PM - 3:15 PM
Location: Mayo Civic Center Rooms 104-105

Epigenomics is a rapidly emerging scientific discipline concerned with the global regulation of genome activity including gene transcription, DNA replication and repair. Recent developments in the understanding of epigenetic mechanisms and their role in producing distinct normal and diseased phenotypes, together with advances in epigenomic technology and pharmacology have led to accelerated translation of epigenetic concepts and findings to disease biomarkers, clinical tests, and drugs. In this session, leading scientists will discuss how insights from basic and translational research inform the development of novel diagnostic tools and therapeutic clinical trials.

Learning Objectives:

Moderator :
Tamas Ordog, MD

Professor of Physiology, College of Medicine and Science
Physiology and Biomedical Engineering, Gastroenterology and Hepatology, and Center for Individualized Medicine
Mayo Clinic
Rochester, Minnesota

Tamas Ordog, MD is Professor and Consultant in the Department of Physiology and Biomedical Engineering and the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota, and founding Director of the Epigenomics Program of the Mayo Clinic Center for Individualized Medicine (CIM). He received predoctoral training in molecular endocrinology at the University of Pécs, Hungary and postdoctoral training in integrative neuroendocrinology at The University of Texas – Houston Health Science Center. Dr. Ordog has studied the cellular and molecular basis of gastrointestinal neuromuscular control in health and disease since 1998. His current research focuses on epigenetic control of cellular phenotypes in the lineage of gastrointestinal pacemaker/neuromodulator cells in aging, diabetes, caloric restriction and oncogenesis, transcriptional and epigenetic regulation of nitric oxide biosynthesis in enteric neurons, as well as on the development of epigenomic technology. As Director of the Mayo Clinic CIM Epigenomics Program, he is leading the effort to employ epigenomic approaches and testing in human diseases


Send Email for Tamas Ordog

Concurrent Speaker :
Ping Chi, MD, PhD

Associate Member and Associate Attending Physician
Human Oncology and Pathogenesis Program and Department of Medicine
Memorial Sloan Kettering Cancer Center
New York

Ping Chi, MD, PhD is an Associate Member in the Human Oncology and Pathogenesis Program (HOPP), and an Associate Attending Physician in the Sarcoma Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center. She completed clinical training in Internal Medicine at the Brigham and Woman’s Hospital and Medical Oncology at Memorial Sloan-Kettering Cancer Center, and a concurrent postdoctoral training in epigenetics and chromatin biology in the C. David Allis’ lab at the Rockefeller University. Her laboratory research focuses on understanding the genetic and epigenetic mechanisms of transcriptional activation of novel oncogenic transcripts and oncogenic transcription factors in solid tumor malignancies, particularly in sarcomas and melanomas. Through mechanistic studies, she aims to identify novel therapeutic strategies to target oncogenic transcription factors and novel mechanisms of aberrant transcriptional activation of oncogenes. She also maintains an active academic clinical practice, leads early phase clinical trials and works with a multidisciplinary team to care for patients with melanoma and sarcomas, with the goal to expedite clinical translation of laboratory research.


Send Email for Ping Chi

Concurrent Speaker :
Jean-Pierre Issa, MD

Professor of Medicine and Director
Fels Institute for Cancer Research & Molecular Biology
Temple University
Philadelphia, Pennsylvania

Jean-Pierre Issa, MD and his laboratory have made significant contributions to the understanding of epigenetics in the pathophysiology and treatment of cancer. Some of his lab’s discoveries include the effects of aging (1994) and inflammation (2000) on promoter DNA methylation, the CpG Island Methylator Phenotype (1999), methylation-independent gene silencing in cancer by Polycomb group proteins (2008), and a link between epigenetics and the microbiome in colon cancer (2014). Starting in 2000, his group initiated laboratory research directed clinical trials that showed that low doses of hypomethylating drugs specifically target DNA methylation and are optimal in the treatment of leukemias. This work contributed to the FDA approval of decitabine in 2006, and led to a large number of epigenetic therapy clinical trials in different malignancies. His current research focuses on mechanisms of epigenetic alterations in aging and cancer, translation of epigenomic studies for precision me dicine, development of drugs for reprogramming the epigenome, and clinical trials of epigenetic therapy in cancer. Dr. Issa’s research has been recognized by numerous awards including a Sidney Kimmell Foundation Scholar Award in 1997, election to the American Society of Clinical Investigation in 2003, an American Cancer Society Clinical Research Professorship in 2007, the Faculty Achievement Award in Basic Research from MD Anderson in 2007, the Rosenthal Award from the American Association for Cancer Research in 2011, and election to the American Association of Physicians in 2015.

Dr. Issa received his undergraduate training and his MD from the American University of Beirut followed by residency in internal medicine at Good Samaritan Hospital and fellowship in Medical Oncology at the Johns Hopkins Oncology Center in Baltimore. He was on the faculty at Johns Hopkins from 1994-1999 and at the University of Texas MD Anderson Cancer Center from 1999-2011. Dr. Issa is an American Cancer Society Clinical Research Professor of Medicine. He is Director of Fels Institute for Cancer Research and Molecular Biology at Temple University School of Medicine as well as Co-Leader of the Program in Cancer Epigenetics at Fox Chase Cancer Center, Temple Health.


Send Email for Jean-Pierre Issa

Concurrent Speaker - Int:
David R. Mole, FRCP

Professor of Renal Medicine
Nuffield Department of Medicine
University of Oxford
Oxford, United Kingdom

David Mole is currently an NIHR Research Professor and Honorary Consultant Nephrologist in the Nuffield Department of Medicine at the University of Oxford. He undertook his medical training as a graduate student at King’s College, London and at Southampton University having previously studied Natural Sciences (Physics and Theoretical Physics) at Cambridge University. He completed his SHO training in General Medicine in Stoke-on-Trent before moving to Reading and Oxford for his higher specialist training in Nephrology and General Medicine. During this time he was awarded a Wellcome Trust Clinical Training Fellowship, leading to a DPhil on the “Analysis of the HIF-pVHL interaction,” which helped to define the nature of cellular oxygen sensing and to illuminate the molecular mechanisms of kidney cancer. Since then he has continued his interest in this field, holding the positions of Clinical Lecturer, Wellcome Trust Intermediate Fellow, and HEFCE Clinical Senior Lecturer alongside his NHS role as a Consultant Nephrologist. He has recently been awarded a highly prestigious NIHR Research Professorship to continue his work on hypoxia pathways in kidney cancer and their application to clinical medicine.


Send Email for David Mole


Concurrent Session 4B: Advancing Care Through Epigenomics; CME (AMA PRA Category 1 CreditsTM) 1.5; Attendance CEU 1.5


Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Concurrent Session 4B: Advancing Care Through Epigenomics; CME (AMA PRA Category 1 CreditsTM) 1.5; Attendance CEU 1.5